Polyrizon Ltd. (Nasdaq: PLRZ), a biotechnology company specializing in intranasal drug delivery systems, has announced promising preclinical results from its recent study on the Trap & Target (T&T) platform, an innovative hydrogel-based formulation. Conducted in collaboration with the University of Parma, Italy, the study demonstrated successful targeted deposition in the upper nasal cavity, crucial for central nervous system $(CNS)$ drug delivery. The hydrogel formulation achieved over 60% preferential accumulation in areas favorable for nose-to-brain transport, indicating potential applications for CNS-related conditions such as opioid overdose and epileptic seizures. Polyrizon plans to continue preclinical development and initiate safety studies to further validate these findings.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。